Got $ 500? 2 Absurdly Cheap Stocks Long-Term Investors Should Buy Now
There is no shame in looking for the right deals when it comes to stocks. While a cheap per share price by itself doesn’t necessarily indicate that a stock is a good investment, it doesn’t mean it’s a bad one, either.
Here are two low-cost stocks that long-term investors should consider grabbing now.
1. Jushi Holdings
Trading for less than $ 6 per share at the time of writing this article, Jushi Holdings (OTC: JUSHF) is a small-cap company with significant potential for long-term growth. The multi-state cannabis operator owns a family of marijuana brands, including Tasteology, Nira and The Lab Concentrates. She also operates a chain of retail cannabis stores spread across Pennsylvania, Illinois, California, and Virginia.
2020 has been an extremely profitable and high growth year for Jushi Holdings. It recorded an almost 700% increase in revenue and its gross profits jumped 760%.
Jushi Holdings announced a 30% increase in revenue in the first quarter of 2021. But the company’s lightning-fast growth is not hampering its ability to expand its cash position as it closed the period with a solid $ 168 million in cash and cash equivalents. and short-term investments.
The company is also rapidly expanding its national presence. In April alone, Jushi Holdings completed its acquisition of a group of marijuana growing, manufacturing and distribution facilities in Nevada and announced other pending deals expected to close later this year. In Ohio, his purchase of OhiGrow will make Jushi Holdings the owner of one of the state’s 34 licensed growers – a key market for medical marijuana. And in Massachusetts, where cannabis is legal for medical and recreational purposes, Jushi plans to acquire Nature’s Remedy, which owns a growing and manufacturing facility as well as two retail dispensaries.
As Jushi Holdings continues to grow its presence in the years to come, its balance sheet and share price could also be significantly increased. Now is the perfect time to take advantage of the cheap price of this premium pot stock to capitalize on its long term potential.
Pfizer (NYSE: PFE) rocketed to rock star status during the pandemic when BNT162b2 – which he developed with his German partner, BioNTech – became the first COVID-19 vaccine to obtain emergency use authorization from the United States Food and Drug Administration. Despite the massive success of BNT162b2, now marketed as Comirnaty, not to mention a rock-solid portfolio of other lucrative products that have seen strong sales growth, Pfizer shares are still trading under $ 40. .
Pfizer’s coronavirus vaccine is already having a decisive impact on its track record. The company expects to generate around $ 26 billion in revenue from Comirnaty in 2021 alone, and it just announced on May 7 that it is filing with the FDA for full vaccine approval for use by people under 16. years and older.
In the first quarter of 2021, Pfizer saw an astonishing 42% year-over-year revenue growth. But he has plenty of other products beyond his coronavirus vaccine to build on for future gains. Even excluding BNT162b2 from the picture, the company still recorded excellent revenue growth of 8% compared to the period of the previous year.
In addition to coronavirus vaccine sales, Pfizer’s strong first quarter revenue growth was driven by a steady single-digit and double-digit revenue increase in its core business segments. For example, sales in Pfizer’s oncology, internal medicine and rare disease segments increased by 16%, 10% and 25%, respectively. Among its top-selling drugs, the anticoagulant Eliquis, heart failure drugs Vyndaqel and Vyndamax, and rheumatoid arthritis drug Xeljanz recorded sales gains of 25%, 88% and 18%, respectively. Management now forecasts annual revenues in the range of $ 70.5 billion to $ 72.5 billion.
Pfizer is also an attractive option for investors looking for dividends. The stock is reporting a healthy 4% at the time of writing. Plus, it trades at just 20 times the trailing profits. The combination of Pfizer’s affordability and the attractive mix of growth and value it offers investors makes this stock an easy buy in any market environment.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a premium Motley Fool consulting service. We are motley! Challenging an investment thesis – even one of our own – helps us all to think critically about investing and make decisions that help us become smarter, happier, and richer.